adalimumab
M16-119
Phase 3 small_molecule completed
Quick answer
adalimumab for Pyoderma Gangrenosum is a Phase 3 program (small_molecule) at AbbVie with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AbbVie
- Indication
- Pyoderma Gangrenosum
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed